.. Le-chlorhydrate-de-tamsulosine, 64 4.3. L'efficacité clinique des ?1-bloquants

É. , .. Étude, and V. , Medical therapy of prostatic symptoms, p.77

L. Conseils and A. , 82 8.2. Ne pas s'affoler 82 8.3. Prévention par l'alimentation et le mode de vie, ., p.83

D. Addessi, A. Martire, M. Cannizzaro, C. Porreca, A. Menchinelli et al., Benign prostatic hyperplasia : correlations between receptor density and biding affinity of alpha(1)-adrenoreceptors and several clinical parameters, Urol Int, vol.68, pp.246-250, 2002.

F. Debruyne, A. Jardin, D. Colloi, L. Resel, W. Witjes et al., Sustained-Release Alfuzosin, Finasteride and the Combination of Both in the Treatment of Benign Prostatic Hyperplasia, European Urology, vol.34, issue.3, pp.169-75, 1998.
DOI : 10.1159/000019706

R. Dedhia and K. Mcvary, Phytotherapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia, The Journal of Urology, vol.179, issue.6, pp.2119-2144, 2008.
DOI : 10.1016/j.juro.2008.01.094

F. Debruyne, G. Koch, P. Boyle, C. Da-silva, F. Gillenwater et al., groupe d'étude PERMAL. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia : a 1-year randomized international study, pp.384-92, 2002.

C. Saussine, Prise en charge médicale de l'hypertrophie bénigne de la prostate non compliquée, Presse Med, vol.36, pp.475-80, 2007.

R. Drake, W. Vogl, and A. Mitchell, Gray's Anatomie pour les étudiants, pp.417-428, 2006.

F. Erdemir, A. Harbin, and W. Hellstrom, 5???Alpha Reductase Inhibitors and Erectile Dysfunction: The Connection, The Journal of Sexual Medicine, vol.5, issue.12, pp.2917-2941, 2008.
DOI : 10.1111/j.1743-6109.2008.01001.x

J. Fix, Controlled release delivery system In controlled drug delivery : designing technologies for the future by park kinam, pp.14-24, 2000.

A. Ishani and R. Macdonald, Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis, The American Journal of Medicine, vol.109, issue.8, pp.654-64, 2000.
DOI : 10.1016/S0002-9343(00)00604-5

K. Jensen, Uroflowmetry in elderly men, World Journal of Urology, vol.13, issue.1, pp.21-33, 1995.
DOI : 10.1007/BF00182661

Y. Kakehi, T. Segawa, X. Wu, P. Kulkarni, R. Dhir et al., Down-regulation of macrophage inhibitory cytokine-1/prostate derived factor in benign prostatic hyperplasia, The Prostate, vol.84, issue.4, pp.351-356, 2004.
DOI : 10.1016/S0167-4781(97)00122-X

P. Kamina, Précis d'anatomie clinique, Tome IV. Editions Maloine, pp.197-205, 2005.

S. Khoury and . Mises-au-point, Hypertrophie bénigne de la prostate, Edition française des Laboratoires Debat, p.191, 1984.

R. Kirby, C. Roehrborn, P. Boyle, G. Bartsch, A. Jardin et al., Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasie : the Prospective European Doxazosin and combination Therapy (PREDICT) trial, pp.61-119, 2003.

B. Lardennois, K. Tran, and G. Lebrun, Anatomie physiologique de la glande prostatique

C. Lee, J. Kozlowski, and J. Grayhack, Etiology of benign prostatic hyperplasia, Urol Clin North Am, vol.22, pp.237-246, 1995.

H. Lepor, D. Gup, M. Baumann, and E. Shapiro, Laboratory assessment of terazosin and alpha 1-blockade in prostatic hyperplasia, pp.21-26, 1988.

H. Lepor, W. Williford, M. Barry, M. Brawer, C. Dixon et al., The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasie Study Group, N Engl J Med, vol.22, pp.533-542, 1996.

S. Madersbacher, M. Marszalek, J. Lackner, P. Berger, and G. Schatzl, The Long-Term Outcome of Medical Therapy for BPH, European Urology, vol.51, issue.6, pp.1522-1555, 2007.
DOI : 10.1016/j.eururo.2007.03.034

L. Marks, D. Hess, F. Dorey, L. Macairan, M. et al., Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens, Urology, vol.57, issue.5, pp.999-1005, 2001.
DOI : 10.1016/S0090-4295(00)01052-9

J. Mcconnell, C. Roehrborn, O. Bautista, G. Andriole, . Jr et al., The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia, New England Journal of Medicine, vol.349, issue.25, pp.2387-98, 2003.
DOI : 10.1056/NEJMoa030656

J. Mcnael, Anatomy of the prostate: An historical survey of divergent views, The Prostate, vol.9, issue.1, pp.3-13, 1980.
DOI : 10.1093/ajcp/49.3.347

K. Mcvary, A review of combination therapy in patients with benign prostatic hyperplasia, Clinical Therapeutics, vol.29, issue.3, pp.387-98, 2007.
DOI : 10.1016/S0149-2918(07)80077-4

F. Mostofi and A. Pathologique, In : L'hypertrophie bénigne de la prostate, pp.19-22, 1991.

L. Muldoon and M. I. Resnick, Anatomie normale de la prostate. Echographie prostatique, Editions Pradel, pp.33-39, 1990.

M. Pollan, H. Benghuzzi, and M. Tucci, Growth factor expression in early stages of benign prostatic hyperplasia upon exposure to sustained delivery of androgens, Biomed Sci Instrum, vol.39, pp.329-334, 2003.

C. Roehrborn, P. Boyle, D. Bergner, T. Gray, M. Gittelman et al., Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo, Urology, vol.54, issue.4
DOI : 10.1016/S0090-4295(99)00232-0

C. Roehrborn, P. Boyle, C. Nickel, J. Hoefner, K. Andriole et al., on behalf of the ARIA 3001, ARIA 3002, and ARIA 3003 study investigators, Efficacy and safety of a dual inhibitor of 5-alphareductase types 1 and 2 (Dutasteride) in men with benign prostatic hyperplasia, pp.434-475, 2002.

C. Roehrborn, S. Kaplan, W. Noble, M. Lucia, K. Slawin et al., The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH : results from the MTOPS study, J Urol, 2005.

C. Roehrborn, J. Mcconnell, P. Walsh, A. Retik, E. Vaughan et al., Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia, Campbell's Urology, pp.1297-1336, 2002.

R. Rosen, J. Wei, S. Althof, A. Seftel, M. Miner et al., Association of Sexual Dysfunction With Lower Urinary Tract Symptoms of BPH and BPH Medical Therapies: Results From the BPH Registry, Urology, vol.73, issue.3, pp.562-568, 2009.
DOI : 10.1016/j.urology.2008.05.034

H. Rouvière and A. Delmas, Anatomie humaine descriptive, topographique et fonctionnelle

C. Roy, Imagerie de la prostate : principes, applications et perspectives, Editions Masson, pp.2-6, 2005.

S. Schleich and M. Papaioannou, and Other Ethnobotanical Species with Antiandrogenic Activity, Planta Medica, vol.72, issue.9, pp.807-820, 2006.
DOI : 10.1055/s-2006-946638

C. Schulman, J. Cortvriend, J. U. Lock, T. M. Vaage, S. Speakman et al., Tamsulosin, the first prostate-selective ?1 A -adrenoreceptor antagonist Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BHP), Eur Urol, vol.29, pp.145-154, 1996.

E. Szolnoki and E. Reichart, The effect of pygeum africanum on fibroblast growth factor (FGF) and transforming growth factor beta (TGFb1/LAP) expression in animal model, Acta Microbiologica et Immunologica Hungarica, vol.48, issue.1, pp.1-9, 2001.
DOI : 10.1556/AMicr.48.2001.1.1

C. Temml, C. Brössner, G. Schatzl, A. Ponholzer, L. Knoepp et al., The Natural History of Lower Urinary Tract Symptoms over Five Years, European Urology, vol.43, issue.4, pp.374-380, 2003.
DOI : 10.1016/S0302-2838(03)00084-8

S. Vesely, T. Knutson, D. J. Dicuio, M. Dahlstrand, and C. , Relationship Between Age, Prostate Volume, Prostate-specific Antigen, Symptom Score and Uroflowmetry in Men with Lower Urinary Tract Symptoms, Scandinavian Journal of Urology and Nephrology, vol.53, issue.1, pp.322-328, 2003.
DOI : 10.1016/S0090-4295(98)00655-4

T. Wilt, A. Ishani, R. Macdonald, I. Rutks, and G. Stark, Pygeum africanum for benign prostatic hyperplasia. (Cochrane Review) In: The Cochrane Library, 2002.
DOI : 10.1002/14651858.cd001044

T. Wilt, A. Ishani, I. Rutks, and R. Macdonald, Phytotherapy for benign prostatic hyperplasia, Public Health Nutr, vol.3, pp.459-72, 2000.
DOI : 10.1017/s1368980000000549

T. Wilt, A. Ishani, G. Stark, R. Macdonald, J. Lau et al., Saw Palmetto Extracts for Treatment of Benign Prostatic Hyperplasia, JAMA, vol.280, issue.18, pp.1604-1613, 1998.
DOI : 10.1001/jama.280.18.1604

T. Wilt, A. Ishani, G. Stark, R. Macdonald, C. Mulrow et al., Serenoa repens for benign prostatic hyperplasia (Cochrane Review) In: The Cochrane Library, 2001.

F. Yablonsky and V. Nicolas, Antiproliferative Effect of Pygeum Africanum Extract on Rat Prostatic Fibroblasts, The Journal of Urology, vol.157, issue.6, pp.2381-2388, 1997.
DOI : 10.1016/S0022-5347(01)64785-2

T. Yokota, K. Honda, Y. Tsuruya, M. Nomiya, O. Yamaguchi et al., Functional and anatomical effects of hormonally induced experimental prostate growth: A urodynamic model of benign prostatic hyperplasia (BPH) in the beagle, The Prostate, vol.46, issue.2, pp.156-163, 2004.
DOI : 10.1111/j.1464-410X.2000.tb16953.x